Kiovig

Human normal immunoglobulin, the active ingredient in Kiovig, is an immunoglobulin presented as a solution for intravenous use. It provides passive immunity by supplying pooled IgG antibodies and is used in patients with primary immunodeficiency, immune thrombocytopenic purpura, Kawasaki disease and other immune‑mediated conditions.

GNH USA supplies Kiovig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kiovig is an intravenous immunoglobulin used to treat disorders involving immune deficiency or dysregulation. - Primary immunodeficiency diseases: replaces missing antibodies to reduce infection risk. - Immune thrombocytopenic purpura (ITP): raises platelet counts and reduces bleeding. - Kawasaki disease: lowers incidence of coronary artery aneurysms. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability.

Kiovig may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Fever or chills: typically during or shortly after infusion. - Nausea or vomiting: occasional gastrointestinal upset. - Fatigue: transient tiredness post‑infusion. - Muscle aches: mild myalgia. - Injection site reactions: redness or swelling.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: blood clots in veins or arteries. - Renal impairment: acute kidney injury, especially with high‑dose regimens. - Hemolysis: breakdown of red blood cells. - Aseptic meningitis: inflammation of the meninges without infection. - Transfusion‑related acute lung injury (TRALI): acute respiratory distress.

Before using Kiovig, consider the following safety measures. - Assess renal function: monitor creatinine and urine output. - Screen for IgA deficiency: risk of severe allergic reactions. - Evaluate thrombotic risk: avoid in patients with active clotting disorders. - Monitor for hemolysis: check hemoglobin and bilirubin levels. - Observe for signs of infection: ensure no active bacterial infection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kiovig can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy or increase risk of infection. - High‑dose aspirin or anticoagulants: increased bleeding risk.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclophosphamide): may alter immune response. - Diuretics: potential for renal stress. - ACE inhibitors: monitor blood pressure and renal function. - Corticosteroids: may affect infection risk. - Other IVIG products: avoid concurrent administration to prevent overload.